8-K: Alto Neuroscience's Phase 2b Trial for Depression Drug Fails to Meet Primary Endpoint

Alto Neuroscience's Phase 2b trial of ALTO-100 for major depressive disorder did not meet its primary endpoint, though the drug showed a favorable safety profile.

Summary

• Alto Neuroscience announced that its Phase 2b study of ALTO-100 for major depressive disorder (MDD) did not meet its primary endpoint.
• The primary endpoint was measured by the change from baseline in the Montgomery-sberg Depression Rating Scale (MADRS) compared to a placebo.
• The study involved 301 adults with MDD across 34 sites in the U.S.
• ALTO-100 did not show a statistically significant improvement in depressive symptoms compared to the placebo group.
• The drug also did not demonstrate benefit over placebo in pre-specified key secondary analyses.
• However, ALTO-100 maintained a favorable safety and tolerability profile, consistent with previous studies.
• The most common adverse events were headache, nausea, and abnormal dreams, occurring at similar rates to the placebo group.
• The company plans to analyze the full data set to determine the next steps for ALTO-100 in MDD.
• Alto Neuroscience expects its current cash position to fund operations into 2027 and through multiple upcoming clinical readouts.

Sentiment

Score: 3

Explanation: The failure of the Phase 2b trial to meet its primary endpoint is a significant negative, despite the favorable safety profile and strong cash position. The overall sentiment is negative due to the lack of efficacy.

Positives

• ALTO-100 demonstrated a favorable safety and tolerability profile, consistent with previous studies.
• The most common adverse events were similar to the placebo group.
• Alto Neuroscience has a strong cash position expected to fund operations into 2027.
• The company has multiple upcoming clinical readouts, including two in MDD expected in the first half of 2025.

Negatives

• The Phase 2b trial of ALTO-100 did not meet its primary endpoint for treating major depressive disorder.
• ALTO-100 did not show a statistically significant improvement in depressive symptoms compared to placebo.
• The drug did not demonstrate benefit over placebo in pre-specified key secondary analyses.

Risks

• The failure of the Phase 2b trial raises questions about the efficacy of ALTO-100 for treating MDD.
• The company needs to analyze the full data set to determine the next steps for ALTO-100.
• There is a risk that future trials may not be successful.
• The company's financial projections could be inaccurate, requiring more cash than anticipated.

Future Outlook

Alto Neuroscience expects its current cash position to fund operations into 2027 and through multiple upcoming clinical readouts, including two additional readouts in MDD with ALTO-203 and ALTO-300 expected in the first half of 2025.

Management Comments

• Amit Etkin, M.D., Ph.D., stated that they are disheartened by the results but proud of conducting a first-of-its-kind precision biomarker-based study in psychiatry.
• Adam Savitz, M.D., Ph.D., mentioned that while the Phase 2b results did not replicate the Phase 2a trial, they believe their approach to collecting and stratifying based on biomarkers is innovative.

Industry Context

The failure of ALTO-100 to meet its primary endpoint highlights the challenges in developing effective treatments for major depressive disorder, a complex condition with significant unmet needs. The company's focus on precision medicine and biomarker-based approaches is an attempt to improve success rates in this field.

Comparison to Industry Standards

• The failure of ALTO-100 to meet its primary endpoint is a setback, as many clinical trials for depression treatments face similar challenges.
• Companies like Sage Therapeutics and Axsome Therapeutics have had successes in developing novel depression treatments, setting a high bar for new entrants.
• The use of biomarkers to stratify patients is an innovative approach, but the results suggest that more research is needed to refine these methods.
• The company's focus on precision medicine is aligned with a broader industry trend towards personalized treatments, but the results highlight the risks associated with this approach.

Stakeholder Impact

• Shareholders may react negatively to the news of the failed trial.
• Patients with MDD may be disappointed by the lack of progress with ALTO-100.
• Employees may face uncertainty about the future of the ALTO-100 program.
• The company's reputation may be affected by the trial results.

Next Steps

• The company will complete analysis of the full data set to determine the most appropriate next steps for ALTO-100 in MDD.
• The company expects two additional readouts in MDD with ALTO-203 and ALTO-300 in the first half of 2025.

Key Dates

Keywords

ALTO-100, Major Depressive Disorder, MDD, Phase 2b Trial, Clinical Trial, Biomarker, Neuropsychiatric Disorders, Montgomery-sberg Depression Rating Scale, MADRS, Precision Medicine